Literature DB >> 21841316

Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity.

Emilie Mamessier1, Aude Sylvain, Marie-Laure Thibult, Gilles Houvenaeghel, Jocelyne Jacquemier, Rémy Castellano, Anthony Gonçalves, Pascale André, François Romagné, Gilles Thibault, Patrice Viens, Daniel Birnbaum, François Bertucci, Alessandro Moretta, Daniel Olive.   

Abstract

NK cells are a major component of the antitumor immune response and are involved in controlling tumor progression and metastases in animal models. Here, we show that dysfunction of these cells accompanies human breast tumor progression. We characterized human peripheral blood NK (p-NK) cells and malignant mammary tumor-infiltrating NK (Ti-NK) cells from patients with noninvasive and invasive breast cancers. NK cells isolated from the peripheral blood of healthy donors and normal breast tissue were used as controls. With disease progression, we found that expression of activating NK cell receptors (such as NKp30, NKG2D, DNAM-1, and CD16) decreased while expression of inhibitory receptors (such as NKG2A) increased and that this correlated with decreased NK cell function, most notably cytotoxicity. Importantly, Ti-NK cells had more pronounced impairment of their cytotoxic potential than p-NK cells. We also identified several stroma-derived factors, including TGF-β1, involved in tumor-induced reduction of normal NK cell function. Our data therefore show that breast tumor progression involves NK cell dysfunction and that breast tumors model their environment to evade NK cell antitumor immunity. This highlights the importance of developing future therapies able to restore NK cell cytotoxicity to limit/prevent tumor escape from antitumor immunity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21841316      PMCID: PMC3171102          DOI: 10.1172/JCI45816

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  88 in total

Review 1.  TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression.

Authors:  Li Yang; Yanli Pang; Harold L Moses
Journal:  Trends Immunol       Date:  2010-06-01       Impact factor: 16.687

2.  Prevention of breast cancer (part I): epidemiology, risk factors, and risk assessment tools.

Authors:  Maria Tria Tirona; Rajesh Sehgal; Oscar Ballester
Journal:  Cancer Invest       Date:  2010-08       Impact factor: 2.176

3.  PGE2 inhibits natural killer and gamma delta T cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type I-dependent signaling.

Authors:  Ludovic Martinet; Christine Jean; Gilles Dietrich; Jean-Jacques Fournié; Rémy Poupot
Journal:  Biochem Pharmacol       Date:  2010-05-12       Impact factor: 5.858

4.  Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta.

Authors:  Shyam A Patel; Justin R Meyer; Steven J Greco; Kelly E Corcoran; Margarette Bryan; Pranela Rameshwar
Journal:  J Immunol       Date:  2010-04-09       Impact factor: 5.422

5.  Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome.

Authors:  M Carlsten; B C Baumann; M Simonsson; M Jädersten; A-M Forsblom; C Hammarstedt; Y T Bryceson; H-G Ljunggren; E Hellström-Lindberg; K-J Malmberg
Journal:  Leukemia       Date:  2010-07-08       Impact factor: 11.528

6.  Human activated T lymphocytes modulate IDO expression in tumors through Th1/Th2 balance.

Authors:  Jessica Godin-Ethier; Sandy Pelletier; Laïla-Aïcha Hanafi; Philippe O Gannon; Marie-Andrée Forget; Jean-Pierre Routy; Mohamed-Rachid Boulassel; Urszula Krzemien; Simon Tanguay; Jean-Baptiste Lattouf; Nathalie Arbour; Réjean Lapointe
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

7.  NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting.

Authors:  Roger W McGilvray; Robert A Eagle; Nicholas F S Watson; Ahmad Al-Attar; Graham Ball; Insiya Jafferji; John Trowsdale; Lindy G Durrant
Journal:  Clin Cancer Res       Date:  2009-10-27       Impact factor: 12.531

8.  In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer.

Authors:  Franck Pagès; Amos Kirilovsky; Bernhard Mlecnik; Martin Asslaber; Marie Tosolini; Gabriela Bindea; Christine Lagorce; Philippe Wind; Florence Marliot; Patrick Bruneval; Kurt Zatloukal; Zlatko Trajanoski; Anne Berger; Wolf-Herman Fridman; Jérôme Galon
Journal:  J Clin Oncol       Date:  2009-10-26       Impact factor: 44.544

9.  Functional analysis of human NK cells by flow cytometry.

Authors:  Yenan T Bryceson; Cyril Fauriat; João M Nunes; Stephanie M Wood; Niklas K Björkström; Eric O Long; Hans-Gustaf Ljunggren
Journal:  Methods Mol Biol       Date:  2010

Review 10.  The polarization of immune cells in the tumour environment by TGFbeta.

Authors:  Richard A Flavell; Shomyseh Sanjabi; Stephen H Wrzesinski; Paula Licona-Limón
Journal:  Nat Rev Immunol       Date:  2010-07-09       Impact factor: 53.106

View more
  250 in total

1.  IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.

Authors:  Joe-Marc Chauvin; Mignane Ka; Ornella Pagliano; Carmine Menna; Quanquan Ding; Richelle DeBlasio; Cindy Sanders; Jiajie Hou; Xian-Yang Li; Soldano Ferrone; Diwakar Davar; John M Kirkwood; Robert J Johnston; Alan J Korman; Mark J Smyth; Hassane M Zarour
Journal:  Clin Cancer Res       Date:  2020-06-26       Impact factor: 12.531

2.  Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy.

Authors:  Caroline Veuillen; Thérèse Aurran-Schleinitz; Rémy Castellano; Jérôme Rey; Françoise Mallet; Florence Orlanducci; Laurent Pouyet; Sylvaine Just-Landi; Diane Coso; Vadim Ivanov; Xavier Carcopino; Réda Bouabdallah; Yves Collette; Cyril Fauriat; Daniel Olive
Journal:  J Clin Immunol       Date:  2012-02-09       Impact factor: 8.317

3.  The breast tumor microenvironment alters the phenotype and function of natural killer cells.

Authors:  Tamara Krneta; Amy Gillgrass; Marianne Chew; Ali A Ashkar
Journal:  Cell Mol Immunol       Date:  2015-08-17       Impact factor: 11.530

Review 4.  The Multifaceted Nature of Tumor Microenvironment in Breast Carcinomas.

Authors:  Laura Annaratone; Eliano Cascardi; Elena Vissio; Ivana Sarotto; Ewa Chmielik; Anna Sapino; Enrico Berrino; Caterina Marchiò
Journal:  Pathobiology       Date:  2020-04-23       Impact factor: 4.342

5.  CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis.

Authors:  Hyun-Bae Jie; Patrick J Schuler; Steve C Lee; Raghvendra M Srivastava; Athanassios Argiris; Soldano Ferrone; Theresa L Whiteside; Robert L Ferris
Journal:  Cancer Res       Date:  2015-04-01       Impact factor: 12.701

6.  Homo-oligomerization of the activating natural killer cell receptor NKp30 ectodomain increases its binding affinity for cellular ligands.

Authors:  Julia Herrmann; Hannah Berberich; Jessica Hartmann; Steffen Beyer; Karen Davies; Joachim Koch
Journal:  J Biol Chem       Date:  2013-11-25       Impact factor: 5.157

7.  The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions.

Authors:  Christopher J Chan; Ludovic Martinet; Susan Gilfillan; Fernando Souza-Fonseca-Guimaraes; Melvyn T Chow; Liam Town; David S Ritchie; Marco Colonna; Daniel M Andrews; Mark J Smyth
Journal:  Nat Immunol       Date:  2014-03-23       Impact factor: 25.606

8.  Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation.

Authors:  Rebecca L Vartuli; Hengbo Zhou; Lingdi Zhang; Rani K Powers; Jared Klarquist; Pratyaydipta Rudra; Melanie Y Vincent; Debashis Ghosh; James C Costello; Ross M Kedl; Jill E Slansky; Rui Zhao; Heide L Ford
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

Review 9.  Targeting PVR (CD155) and its receptors in anti-tumor therapy.

Authors:  Paola Kučan Brlić; Tihana Lenac Roviš; Guy Cinamon; Pini Tsukerman; Ofer Mandelboim; Stipan Jonjić
Journal:  Cell Mol Immunol       Date:  2018-10-01       Impact factor: 11.530

10.  Natural killer cells phenotypic characterization as an outcome predictor of HCV-linked HCC after curative treatments.

Authors:  Elisabetta Cariani; Massimo Pilli; Valeria Barili; Emanuela Porro; Elisabetta Biasini; Andrea Olivani; Raffaele Dalla Valle; Tommaso Trenti; Carlo Ferrari; Gabriele Missale
Journal:  Oncoimmunology       Date:  2016-03-04       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.